202 related articles for article (PubMed ID: 37284741)
1. Characterization of candidate factors associated with the metastasis and progression of high-grade serous ovarian cancer.
Liu H; Zhou L; Cheng H; Wang S; Luan W; Cai E; Ye X; Zhu H; Cui H; Li Y; Chang X
Chin Med J (Engl); 2023 Dec; 136(24):2974-2982. PubMed ID: 37284741
[TBL] [Abstract][Full Text] [Related]
2. Identification of Hub Genes in High-Grade Serous Ovarian Cancer Using Weighted Gene Co-Expression Network Analysis.
Wu M; Sun Y; Wu J; Liu G
Med Sci Monit; 2020 Mar; 26():e922107. PubMed ID: 32180586
[TBL] [Abstract][Full Text] [Related]
3. High expression of fibroblast activation protein (FAP) predicts poor outcome in high-grade serous ovarian cancer.
Li M; Cheng X; Rong R; Gao Y; Tang X; Chen Y
BMC Cancer; 2020 Oct; 20(1):1032. PubMed ID: 33109151
[TBL] [Abstract][Full Text] [Related]
4. Identification of metastasis and prognosis-associated genes for serous ovarian cancer.
Yang Y; Qi S; Shi C; Han X; Yu J; Zhang L; Qin S; Gao Y
Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32510146
[TBL] [Abstract][Full Text] [Related]
5. Development and validation of an individualized gene expression-based signature to predict overall survival of patients with high-grade serous ovarian carcinoma.
Yuan D; Zhu H; Wang T; Zhang Y; Zheng X; Qu Y
Eur J Med Res; 2023 Oct; 28(1):465. PubMed ID: 37884970
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Lymphoid Structures Are Associated with a Favorable Prognosis in High-Grade Serous Ovarian Cancer Patients.
Zhang K; Xie X; Zou LH; Guo SQ
Reprod Sci; 2023 Aug; 30(8):2468-2480. PubMed ID: 36759495
[TBL] [Abstract][Full Text] [Related]
7. Model constructions of chemosensitivity and prognosis of high grade serous ovarian cancer based on evaluation of immune microenvironment and immune response.
Zhang H; Wu Y; Li H; Sun L; Meng X
Cancer Cell Int; 2021 Nov; 21(1):593. PubMed ID: 34736480
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
9. Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.
Si M; Zhang J; Cao J; Xie Z; Shu S; Zhu Y; Lang J
Onco Targets Ther; 2019; 12():10057-10075. PubMed ID: 31819501
[TBL] [Abstract][Full Text] [Related]
10. A Comprehensive Analysis of Prognostic Indicators in Serous Ovarian Cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract][Full Text] [Related]
11. Tumor specific methylome in Chinese high-grade serous ovarian cancer characterized by gene expression profile and tumor genotype.
Song F; Li L; Zhang B; Zhao Y; Zheng H; Yang M; Li X; Tian J; Huang C; Liu L; Wang Q; Zhang W; Chen K
Gynecol Oncol; 2020 Jul; 158(1):178-187. PubMed ID: 32362568
[TBL] [Abstract][Full Text] [Related]
12. Comparative transcriptome analysis of matched primary and distant metastatic ovarian carcinoma.
Sallinen H; Janhonen S; Pölönen P; Niskanen H; Liu OH; Kivelä A; Hartikainen JM; Anttila M; Heinäniemi M; Ylä-Herttuala S; Kaikkonen MU
BMC Cancer; 2019 Nov; 19(1):1121. PubMed ID: 31744494
[TBL] [Abstract][Full Text] [Related]
13. Screening differentially expressed genes between endometriosis and ovarian cancer to find new biomarkers for endometriosis.
Lu Z; Gao Y
Ann Med; 2021 Dec; 53(1):1377-1389. PubMed ID: 34409913
[TBL] [Abstract][Full Text] [Related]
14. Bioinformatic profiling identifies a platinum-resistant-related risk signature for ovarian cancer.
Wu C; He L; Wei Q; Li Q; Jiang L; Zhao L; Wang C; Li J; Wei M
Cancer Med; 2020 Feb; 9(3):1242-1253. PubMed ID: 31856408
[TBL] [Abstract][Full Text] [Related]
15. Identification of Differentially Expressed Genes (DEGs) Relevant to Prognosis of Ovarian Cancer by Use of Integrated Bioinformatics Analysis and Validation by Immunohistochemistry Assay.
Zhang L; Sun L; Zhang B; Chen L
Med Sci Monit; 2019 Dec; 25():9902-9912. PubMed ID: 31871312
[TBL] [Abstract][Full Text] [Related]
16. Deciphering the immune landscape dominated by cancer-associated fibroblasts to investigate their potential in indicating prognosis and guiding therapeutic regimens in high grade serous ovarian carcinoma.
Li Y; Tian R; Liu J; Li J; Tan H; Wu Q; Fu X
Front Immunol; 2022; 13():940801. PubMed ID: 36119108
[TBL] [Abstract][Full Text] [Related]
17. Integrated bioinformatics analysis for the screening of hub genes and therapeutic drugs in ovarian cancer.
Yang D; He Y; Wu B; Deng Y; Wang N; Li M; Liu Y
J Ovarian Res; 2020 Jan; 13(1):10. PubMed ID: 31987036
[TBL] [Abstract][Full Text] [Related]
18. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer.
Zhang L; Fu R; Liu P; Wang L; Liang W; Zou H; Jia W; Tao L
J Ovarian Res; 2021 Nov; 14(1):149. PubMed ID: 34736492
[TBL] [Abstract][Full Text] [Related]
19. Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
Wu Y; Xia L; Zhao P; Deng Y; Guo Q; Zhu J; Chen X; Ju X; Wu X
Aging (Albany NY); 2020 Jun; 12(12):11398-11415. PubMed ID: 32544083
[TBL] [Abstract][Full Text] [Related]
20. Identification of molecular marker associated with ovarian cancer prognosis using bioinformatics analysis and experiments.
Zheng MJ; Li X; Hu YX; Dong H; Gou R; Nie X; Liu Q; Ying-Ying H; Liu JJ; Lin B
J Cell Physiol; 2019 Jul; 234(7):11023-11036. PubMed ID: 30633343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
